Sinclair Pharma PLC (LON:SPH)‘s stock had its “buy” rating reiterated by equities researchers at Stifel Nicolaus in a report issued on Wednesday. They currently have a GBX 63 ($0.82) price target on the specialty pharmaceutical company’s stock. Stifel Nicolaus’ target price would suggest a potential upside of 133.33% from the company’s current price.

A number of other equities analysts have also weighed in on SPH. Peel Hunt reiterated a “buy” rating and issued a GBX 66 ($0.86) price target on shares of Sinclair Pharma PLC in a research report on Thursday, May 26th. Jefferies Group decreased their price target on Sinclair Pharma PLC from GBX 60 ($0.78) to GBX 55 ($0.72) and set a “buy” rating for the company in a research report on Wednesday, June 15th. N+1 Singer reiterated a “buy” rating on shares of Sinclair Pharma PLC in a research report on Wednesday. Finally, Royal Bank Of Canada reiterated an “outperform” rating on shares of Sinclair Pharma PLC in a research report on Thursday, September 15th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of GBX 57 ($0.74).

Shares of Sinclair Pharma PLC (LON:SPH) opened at 27.32999 on Wednesday. The stock’s market cap is GBX 135.83 million. The stock’s 50 day moving average price is GBX 29.84 and its 200-day moving average price is GBX 32.69. Sinclair Pharma PLC has a one year low of GBX 26.25 and a one year high of GBX 61.33.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/sinclair-pharma-plc-sph-earns-buy-rating-from-stifel-nicolaus.html

About Sinclair Pharma PLC

Sinclair Pharma plc, formerly Sinclair IS Pharma plc, is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the manufacture and wholesale distribution of dermatological products. Its segments are Country Operations, which include its operations in France, the United Kingdom, Italy, Germany and Spain, and International Operations, under which the Company sells through a local distributor.

Receive News & Ratings for Sinclair Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinclair Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.